Natural History of β-Cell Autoimmunity in Young Children with Increased Genetic Susceptibility to Type 1 Diabetes Recruited from the General Population

The aim of this study was to evaluate the frequency and predictive value of diabetes-associated autoantibodies, such as islet cell antibodies (ICA) and autoantibodies to insulin (IAA), GAD65 (GADA), and the IA-2 molecule (IA-2A) in genetically susceptible children from the general population during...

Full description

Saved in:
Bibliographic Details
Published inThe journal of clinical endocrinology and metabolism Vol. 87; no. 10; pp. 4572 - 4579
Main Authors Kimpimäki, T, Kulmala, P, Savola, K, Kupila, A, Korhonen, S, Simell, T, Ilonen, J, Simell, O, Knip, M
Format Journal Article
LanguageEnglish
Published United States Endocrine Society 01.10.2002
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The aim of this study was to evaluate the frequency and predictive value of diabetes-associated autoantibodies, such as islet cell antibodies (ICA) and autoantibodies to insulin (IAA), GAD65 (GADA), and the IA-2 molecule (IA-2A) in genetically susceptible children from the general population during the first 2 yr of life. Of 12,170 newborn infants, 1,005 with increased genetic risk of type 1 diabetes (high risk, human leukocyte antigen DQB1*02/*0302; moderate risk, DQB1*0302/x, where x = other than *02, *0301, or *0602) were monitored for ICA, IAA, GADA, and IA-2A at 3- to 6-month intervals from birth up to a minimum age of 2 yr. In addition, all 15 genetically susceptible children from the general population who had participated in regular immunological follow-up and developed clinical type 1 diabetes by the end of April 2000 were analyzed for the development of autoantibodies. Among 1,005 children, 63 (6.3%) tested positive for at least one autoantibody, 31 for ICA (3.1%), 48 for IAA (4.8%), 23 for GADA (2.3%), and 13 for IA-2A (1.3%) at least once by the age of 2 yr. Both ICA and IAA identified 95% [95% confidence interval (CI), 77.2–99.9%] of those who tested persistently positive for multiple (≥2) antibodies at the age of 2 yr, GADA identified 86% (CI, 65.1–97.1%), and IA-2A identified 55% (CI, 32.2–75.6%). Close to half of the antibody-positive children (29 of 63) reverted back to antibody negativity. Autoantibodies disappeared more often among those who tested positive for IAA than among those who tested positive for other autoantibodies (P ≤ 0.021). Among the 15 children who developed type 1 diabetes, the disease sensitivity of ICA was 80% (CI, 51.9–95.7%), that of IAA was 93% (CI, 68.0–99.8%), that of GADA was 60% (CI, 32.3–83.7%), and that of IA-2A was 40% (CI, 16.3–67.7%). These results suggest that IAA are characterized by high sensitivity, early appearance, and high frequency of transient antibody positivity, whereas ICA detected with a thoroughly standardized assay appear to be more specific for the screening of β-cell autoimmunity in young children with increased genetic susceptibility to type 1 diabetes in the Finnish population, which has the highest incidence of type 1 diabetes in the world.
AbstractList The aim of this study was to evaluate the frequency and predictive value of diabetes-associated autoantibodies, such as islet cell antibodies (ICA) and autoantibodies to insulin (IAA), GAD65 (GADA), and the IA-2 molecule (IA-2A) in genetically susceptible children from the general population during the first 2 yr of life. Of 12,170 newborn infants, 1,005 with increased genetic risk of type 1 diabetes (high risk, human leukocyte antigen DQB1*02/*0302; moderate risk, DQB1*0302/x, where x = other than *02, *0301, or *0602) were monitored for ICA, IAA, GADA, and IA-2A at 3- to 6-month intervals from birth up to a minimum age of 2 yr. In addition, all 15 genetically susceptible children from the general population who had participated in regular immunological follow-up and developed clinical type 1 diabetes by the end of April 2000 were analyzed for the development of autoantibodies. Among 1,005 children, 63 (6.3%) tested positive for at least one autoantibody, 31 for ICA (3.1%), 48 for IAA (4.8%), 23 for GADA (2.3%), and 13 for IA-2A (1.3%) at least once by the age of 2 yr. Both ICA and IAA identified 95% [95% confidence interval (CI), 77.2-99.9%] of those who tested persistently positive for multiple (> or = 2) antibodies at the age of 2 yr, GADA identified 86% (CI, 65.1-97.1%), and IA-2A identified 55% (CI, 32.2-75.6%). Close to half of the antibody-positive children (29 of 63) reverted back to antibody negativity. Autoantibodies disappeared more often among those who tested positive for IAA than among those who tested positive for other autoantibodies (P < or = 0.021). Among the 15 children who developed type 1 diabetes, the disease sensitivity of ICA was 80% (CI, 51.9-95.7%), that of IAA was 93% (CI, 68.0-99.8%), that of GADA was 60% (CI, 32.3-83.7%), and that of IA-2A was 40% (CI, 16.3-67.7%). These results suggest that IAA are characterized by high sensitivity, early appearance, and high frequency of transient antibody positivity, whereas ICA detected with a thoroughly standardized assay appear to be more specific for the screening of beta-cell autoimmunity in young children with increased genetic susceptibility to type 1 diabetes in the Finnish population, which has the highest incidence of type 1 diabetes in the world.
The aim of this study was to evaluate the frequency and predictive value of diabetes-associated autoantibodies, such as islet cell antibodies (ICA) and autoantibodies to insulin (IAA), GAD65 (GADA), and the IA-2 molecule (IA-2A) in genetically susceptible children from the general population during the first 2 yr of life. Of 12,170 newborn infants, 1,005 with increased genetic risk of type 1 diabetes (high risk, human leukocyte antigen DQB1*02/*0302; moderate risk, DQB1*0302/x, where x = other than *02, *0301, or *0602) were monitored for ICA, IAA, GADA, and IA-2A at 3- to 6-month intervals from birth up to a minimum age of 2 yr. In addition, all 15 genetically susceptible children from the general population who had participated in regular immunological follow-up and developed clinical type 1 diabetes by the end of April 2000 were analyzed for the development of autoantibodies. Among 1,005 children, 63 (6.3%) tested positive for at least one autoantibody, 31 for ICA (3.1%), 48 for IAA (4.8%), 23 for GADA (2.3%), and 13 for IA-2A (1.3%) at least once by the age of 2 yr. Both ICA and IAA identified 95% [95% confidence interval (CI), 77.2-99.9%] of those who tested persistently positive for multiple (> or = 2) antibodies at the age of 2 yr, GADA identified 86% (CI, 65.1-97.1%), and IA-2A identified 55% (CI, 32.2-75.6%). Close to half of the antibody-positive children (29 of 63) reverted back to antibody negativity. Autoantibodies disappeared more often among those who tested positive for IAA than among those who tested positive for other autoantibodies (P < or = 0.021). Among the 15 children who developed type 1 diabetes, the disease sensitivity of ICA was 80% (CI, 51.9-95.7%), that of IAA was 93% (CI, 68.0-99.8%), that of GADA was 60% (CI, 32.3-83.7%), and that of IA-2A was 40% (CI, 16.3-67.7%). These results suggest that IAA are characterized by high sensitivity, early appearance, and high frequency of transient antibody positivity, whereas ICA detected with a thoroughly standardized assay appear to be more specific for the screening of beta-cell autoimmunity in young children with increased genetic susceptibility to type 1 diabetes in the Finnish population, which has the highest incidence of type 1 diabetes in the world.
The aim of this study was to evaluate the frequency and predictive value of diabetes-associated autoantibodies, such as islet cell antibodies (ICA) and autoantibodies to insulin (IAA), GAD65 (GADA), and the IA-2 molecule (IA-2A) in genetically susceptible children from the general population during the first 2 yr of life. Of 12,170 newborn infants, 1,005 with increased genetic risk of type 1 diabetes (high risk, human leukocyte antigen DQB1*02/*0302; moderate risk, DQB1*0302/x, where x = other than *02, *0301, or *0602) were monitored for ICA, IAA, GADA, and IA-2A at 3- to 6-month intervals from birth up to a minimum age of 2 yr. In addition, all 15 genetically susceptible children from the general population who had participated in regular immunological follow-up and developed clinical type 1 diabetes by the end of April 2000 were analyzed for the development of autoantibodies. Among 1,005 children, 63 (6.3%) tested positive for at least one autoantibody, 31 for ICA (3.1%), 48 for IAA (4.8%), 23 for GADA (2.3%), and 13 for IA-2A (1.3%) at least once by the age of 2 yr. Both ICA and IAA identified 95% [95% confidence interval (CI), 77.2–99.9%] of those who tested persistently positive for multiple (≥2) antibodies at the age of 2 yr, GADA identified 86% (CI, 65.1–97.1%), and IA-2A identified 55% (CI, 32.2–75.6%). Close to half of the antibody-positive children (29 of 63) reverted back to antibody negativity. Autoantibodies disappeared more often among those who tested positive for IAA than among those who tested positive for other autoantibodies (P ≤ 0.021). Among the 15 children who developed type 1 diabetes, the disease sensitivity of ICA was 80% (CI, 51.9–95.7%), that of IAA was 93% (CI, 68.0–99.8%), that of GADA was 60% (CI, 32.3–83.7%), and that of IA-2A was 40% (CI, 16.3–67.7%). These results suggest that IAA are characterized by high sensitivity, early appearance, and high frequency of transient antibody positivity, whereas ICA detected with a thoroughly standardized assay appear to be more specific for the screening of β-cell autoimmunity in young children with increased genetic susceptibility to type 1 diabetes in the Finnish population, which has the highest incidence of type 1 diabetes in the world.
Author Kimpimäki, T
Savola, K
Simell, O
Kulmala, P
Ilonen, J
Korhonen, S
Knip, M
Simell, T
Kupila, A
Author_xml – sequence: 1
  givenname: T
  surname: Kimpimäki
  fullname: Kimpimäki, T
– sequence: 2
  givenname: P
  surname: Kulmala
  fullname: Kulmala, P
– sequence: 3
  givenname: K
  surname: Savola
  fullname: Savola, K
– sequence: 4
  givenname: A
  surname: Kupila
  fullname: Kupila, A
– sequence: 5
  givenname: S
  surname: Korhonen
  fullname: Korhonen, S
– sequence: 6
  givenname: T
  surname: Simell
  fullname: Simell, T
– sequence: 7
  givenname: J
  surname: Ilonen
  fullname: Ilonen, J
– sequence: 8
  givenname: O
  surname: Simell
  fullname: Simell, O
– sequence: 9
  givenname: M
  surname: Knip
  fullname: Knip, M
BackLink https://www.ncbi.nlm.nih.gov/pubmed/12364437$$D View this record in MEDLINE/PubMed
BookMark eNp1kc9uEzEQxq2qqE0L1x4rn7htsHedePdYpdBWqgBBkeBkeb3jxpHX3vqPUN6E5-iD8Ex1mkicuMwc5vd9mpnvDB077wChC0rmtKbkw0bNa0LqipRK2yM0ox1bVJx2_BjNyoBWHa9_nqKzGDeFYGzRnKBTWjdLxho-Q38-y5SDtPjWxOTDFnuN_z5XK7AWX-XkzThmZ9IWG4d_-ewe8Wpt7BDA4d8mrfGdUwFkhAHfgINkFP6eo4Ipmd7YnS55_LCdAFN8bWQPCSL-Bipkk4pGBz_itIZX8W6Lr37KVibj3Vv0Rksb4d2hn6Mfnz4-rG6r-y83d6ur-0o1nKcKOhgaNTDdyCVlvew0lL_0Ui1h0WrNlOypXPYtBQK8DAc-0JZQyXtS2FY35-j93ncK_ilDTGI05QBrpQOfo-A1ZW3D2wLO96AKPsYAWkzBjDJsBSVil4XYKLHLQuyzKILLg3PuRxj-4YfnF2CxB8ANXgXjYAoQo9j4HFy5-X_GL2T2nJc
CitedBy_id crossref_primary_10_1097_MPG_0b013e31805fc256
crossref_primary_10_1111_j_1753_0407_2010_00102_x
crossref_primary_10_1111_j_1365_2249_2011_04324_x
crossref_primary_10_1210_clinem_dgaa624
crossref_primary_10_1007_s00125_017_4258_7
crossref_primary_10_6065_apem_2014_19_2_76
crossref_primary_10_1111_nyas_12021
crossref_primary_10_2337_dc19_1731
crossref_primary_10_3389_fimmu_2024_1345494
crossref_primary_10_1007_s11892_005_0035_y
crossref_primary_10_2337_diacare_29_03_06_dc05_0774
crossref_primary_10_1017_S0007114510003338
crossref_primary_10_2337_dc16_0181
crossref_primary_10_1111_j_1399_5448_2006_00225_x
crossref_primary_10_1111_j_1399_5448_2007_00349_x
crossref_primary_10_2337_dc10_2324
crossref_primary_10_1016_j_clim_2010_09_002
crossref_primary_10_1084_jem_20081800
crossref_primary_10_1016_j_jaut_2009_04_003
crossref_primary_10_1016_S1696_2818_03_71581_9
crossref_primary_10_1210_jc_2019_01069
crossref_primary_10_1016_j_jfma_2016_07_005
crossref_primary_10_1038_sdata_2018_250
crossref_primary_10_1111_pedi_12812
crossref_primary_10_1007_s00251_017_0999_1
crossref_primary_10_1016_j_autrev_2009_02_019
crossref_primary_10_4049_jimmunol_1000820
crossref_primary_10_1007_s00125_006_0225_4
crossref_primary_10_1002_dmrr_998
crossref_primary_10_1007_s00125_007_0617_0
crossref_primary_10_3390_ijms22147493
crossref_primary_10_1210_jc_2019_00421
crossref_primary_10_1007_s00125_005_1844_x
crossref_primary_10_3389_fendo_2022_933965
crossref_primary_10_1007_s00125_008_0945_8
crossref_primary_10_2337_dc06_0711
crossref_primary_10_3345_kjp_2010_53_3_414
crossref_primary_10_1515_CCLM_2008_138
crossref_primary_10_1111_pedi_12386
crossref_primary_10_1007_s11892_018_1066_5
crossref_primary_10_1016_j_retram_2018_01_003
crossref_primary_10_1002_dmrr_506
crossref_primary_10_1007_s00125_010_1713_0
crossref_primary_10_1016_j_clim_2006_09_004
crossref_primary_10_1136_bmjopen_2021_052449
crossref_primary_10_1002_dmrr_1294
crossref_primary_10_2337_diabetes_54_suppl_2_S25
crossref_primary_10_1007_s00281_017_0665_6
crossref_primary_10_1016_S0929_6646_09_60417_4
crossref_primary_10_1371_journal_pone_0033574
crossref_primary_10_1161_CIRCULATIONAHA_106_641472
crossref_primary_10_1111_j_1399_543X_2005_00129_x
crossref_primary_10_1111_j_1399_5448_2007_00256_x
crossref_primary_10_2337_diacare_27_3_676
crossref_primary_10_31146_1682_8658_ecg_202_6_27_35
crossref_primary_10_4239_wjd_v11_i11_527
crossref_primary_10_1002_bmc_3050
crossref_primary_10_2337_diabetes_53_2_384
crossref_primary_10_1007_s00125_017_4256_9
crossref_primary_10_1111_j_1399_5448_2009_00574_x
crossref_primary_10_1007_s00125_023_06075_3
crossref_primary_10_1080_07435800802080328
crossref_primary_10_1210_endrev_bnab013
crossref_primary_10_1007_s00592_011_0364_z
crossref_primary_10_1016_j_jaut_2004_03_008
crossref_primary_10_2337_diacare_27_12_2784
crossref_primary_10_1016_j_beem_2004_11_009
crossref_primary_10_1111_cei_13391
crossref_primary_10_1007_s00125_024_06205_5
crossref_primary_10_1373_clinchem_2010_148205
crossref_primary_10_2337_diabetes_54_suppl_2_S52
crossref_primary_10_1016_j_clim_2008_11_004
crossref_primary_10_1172_JCI200421307
crossref_primary_10_1210_jc_2004_1371
crossref_primary_10_3109_10408361003787171
crossref_primary_10_3945_ajcn_110_000646
crossref_primary_10_1007_s00125_009_1438_0
crossref_primary_10_1530_EJE_07_0853
crossref_primary_10_1002_dmrr_3132
crossref_primary_10_1515_jpem_2019_0103
crossref_primary_10_1016_j_jaut_2008_01_001
crossref_primary_10_1196_annals_1375_055
crossref_primary_10_1530_REP_13_0614
crossref_primary_10_1016_j_clim_2012_09_010
crossref_primary_10_1136_bmjopen_2018_028578
crossref_primary_10_1371_journal_pone_0051909
crossref_primary_10_1016_S2213_8587_19_30412_7
crossref_primary_10_2337_db13_0300
crossref_primary_10_1111_j_1399_5448_2010_00697_x
crossref_primary_10_1007_s00125_005_1864_6
crossref_primary_10_1016_j_diabres_2021_108798
crossref_primary_10_1007_s11892_008_0017_y
crossref_primary_10_1186_1479_5876_9_203
crossref_primary_10_1016_j_clim_2007_03_545
crossref_primary_10_2337_dc22_1960
crossref_primary_10_1016_j_diabres_2005_10_022
crossref_primary_10_1007_s00125_014_3294_9
crossref_primary_10_1002_dmrr_2864
crossref_primary_10_1586_1744666X_5_1_55
crossref_primary_10_1016_j_cll_2004_01_012
crossref_primary_10_1038_gene_2015_43
crossref_primary_10_1007_s11428_018_0341_z
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1210/jc.2002-020018
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1945-7197
EndPage 4579
ExternalDocumentID 10_1210_jc_2002_020018
12364437
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID -
02
08R
0R
1TH
29K
2WC
34G
39C
3O-
3V.
4.4
48X
53G
55
5GY
5RS
5YH
7X7
88E
8F7
8FI
8FJ
AABJS
AABMN
AAIMJ
AAJQQ
AAPQZ
AAQQT
AAUQX
AAWTL
AAYJJ
ABFLS
ABOCM
ABPMR
ABPPZ
ABSAR
ABUWG
ACGFS
ACIMA
ACPRK
ACUTJ
ADBBV
ADBIT
ADEIU
ADGZP
ADHKW
ADRTK
AELNO
AELWJ
AEMDU
AENEX
AENZO
AETBJ
AEWNT
AFCHL
AFFNX
AFKRA
AFRAH
AFXEN
AGINJ
AGKRT
AGVJH
AHMBA
AIKOY
AIMBJ
ALMA_UNASSIGNED_HOLDINGS
APIBT
AQKUS
ARIXL
ASMCH
ASPBG
AVWKF
AYOIW
AZFZN
AZQFJ
BAWUL
BAYMD
BBAFP
BCRHZ
BENPR
BEYMZ
BGYMP
BHONS
BPHCQ
BSWAC
BTRTY
BVXVI
C45
CDBKE
CS3
D-I
DAKXR
DIK
DPPUQ
E3Z
EBS
EIHJH
EJD
ENERS
F5P
FEDTE
FH7
FHSFR
FOTVD
FQBLK
FYUFA
G8K
GAUVT
GJ
GJXCC
GX1
H1
H13
HVGLF
HZ
H~9
IAO
IHR
INH
J5H
KBUDW
KOP
KQ8
KSN
L7B
M1P
M5
MBLQV
MHKGH
N9A
NLBLG
NOYVH
NVLIB
O0-
O9-
OBH
OCB
ODMLO
OGEVE
OK1
OVD
P2P
PQEST
PQQKQ
PQUKI
PRINS
PROAC
PSQYO
REU
ROX
ROZ
TCN
TJX
TLC
TMA
TWZ
VH1
WOQ
X
X52
X7M
XZ
ZA5
ZGI
ZXP
ZY1
---
-~X
.55
.GJ
.XZ
08P
0R~
18M
354
AABZA
AACZT
AAKAS
AAPGJ
AAPXW
AARHZ
AAUAY
AAVAP
AAWDT
ABBLC
ABJNI
ABLJU
ABMNT
ABNHQ
ABPQP
ABPTD
ABQNK
ABWST
ABXVV
ACFRR
ACGFO
ACYHN
ACZBC
ADGKP
ADQBN
ADVEK
ADZCM
AERZD
AFFZL
AFGWE
AFOFC
AFXAL
AFYAG
AGMDO
AGQXC
AGUTN
AI.
AJEEA
APJGH
AQDSO
ATGXG
AVNTJ
CGR
CUY
CVF
ECM
EIF
EMOBN
FECEO
FLUFQ
FOEOM
HZ~
ITC
KSI
M5~
MJL
N4W
NOMLY
NPM
OAUYM
OFXIZ
OHH
OJZSN
OPAEJ
OVIDX
P6G
TEORI
TR2
VVN
W8F
WHG
YBU
YFH
YHG
YOC
YSK
~02
~H1
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c377t-e9ed3cd4f3a614ba9fe121bac6e58ff4cab1a6b81e0e79fed7d1801a7b0a9f8f3
ISSN 0021-972X
IngestDate Thu Aug 15 23:03:17 EDT 2024
Thu Sep 26 19:14:02 EDT 2024
Sat Sep 28 07:48:32 EDT 2024
Tue Jan 05 21:44:35 EST 2021
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 10
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c377t-e9ed3cd4f3a614ba9fe121bac6e58ff4cab1a6b81e0e79fed7d1801a7b0a9f8f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://academic.oup.com/jcem/article-pdf/87/10/4572/9155409/jcem4572.pdf
PMID 12364437
PQID 72148378
PQPubID 23479
PageCount 8
ParticipantIDs proquest_miscellaneous_72148378
crossref_primary_10_1210_jc_2002_020018
pubmed_primary_12364437
endocrinepress_journals_10_1210_jc_2002_020018
PublicationCentury 2000
PublicationDate 2002-10
2002-Oct
2002-10-00
20021001
PublicationDateYYYYMMDD 2002-10-01
PublicationDate_xml – month: 10
  year: 2002
  text: 2002-10
PublicationDecade 2000
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle The journal of clinical endocrinology and metabolism
PublicationTitleAlternate J Clin Endocrinol Metab
PublicationYear 2002
Publisher Endocrine Society
Publisher_xml – name: Endocrine Society
SSID ssj0014453
Score 2.1495066
Snippet The aim of this study was to evaluate the frequency and predictive value of diabetes-associated autoantibodies, such as islet cell antibodies (ICA) and...
SourceID proquest
crossref
pubmed
endocrinepress
SourceType Aggregation Database
Index Database
Publisher
StartPage 4572
SubjectTerms Aging
Autoantibodies - blood
Autoimmunity - genetics
Diabetes Mellitus, Type 1 - genetics
Diabetes Mellitus, Type 1 - immunology
Genetic Predisposition to Disease
Glutamate Decarboxylase - immunology
Humans
Infant
Insulin Antibodies - blood
Islets of Langerhans - immunology
Isoenzymes - immunology
Title Natural History of β-Cell Autoimmunity in Young Children with Increased Genetic Susceptibility to Type 1 Diabetes Recruited from the General Population
URI http://dx.doi.org/10.1210/jc.2002-020018
https://www.ncbi.nlm.nih.gov/pubmed/12364437
https://search.proquest.com/docview/72148378
Volume 87
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JjtNAEG2FQUIcQOyEtQ6MOESOvLTT8TGEgRHSjEaajJSb1bbbUlBiR8S-8CV8Bx_CP_AnVHW3l6CMNHCxko63uF7X4q56xdg7GSTTIPAxTOWZdMhhxznHEyeTecbdPEgnmuz57HxyesW_LMPlYPC7l7VUV8k4_X6wruR_pIpjKFeqkv0HybYnxQH8jPLFLUoYtzeS8bk0rBmG60OvlR_PT44_-M6cXsnN6qpc6fqPSlf36ZltyIyb8m3SD5SWjm4nEVATe-tlvdOpLjprVvumFKuOvNHH5jUtuZq1dlXb4hTLXj26aPuB9b1ewmKPoqKtxlRFVqLWKjoeqI2qEJXrhtdQJwdstquNXs_npsX2YtytP603cq3d34t28FKixjWFbr0dtyszNhvvvefw24y5ru7AcyKhm6-j5TLqOuKhIzyT4dvoc2vALW7dnnbmoWkTZC09fo0OWhEMg8mKaIZL33Ep7Wza2csmR-AvM9omN1JYhWeIv6bU49OPzfG32G1fRCFlnX5etllIGM5aolT75yyvKBVW7V9_z2-618jHZEtfHx1pL2nxgN234Q3MDFYfsoEqHrE7ZzaB4zH7YSELFrJQ5vDrp4Yr9OEKqwI0XKGBKxBcoYUrWLjCPlyhKoHgCh40cIUWrkBwBYQrWLhCB9cn7OrTyWJ-6tjmIE4aCFE5KlJZkGY8DyR6mImMcoVPLZHpRIXTPOepTDw5SaaecpXAHzOReeiNSZG4uO80D56yo6Is1HMGrsSoWXA5ibKAE5E1wioLvBTVmJ-GUTRk75tHH28NB0x8WMhDNt6XTGwn1-7aA942kotRr9NinSxUWe9i4Xu62cOQPTMC7S5NPR94IF7c-LZesrvdjHrFjqpvtXqNvnSVvNFo_APaH8tY
link.rule.ids 315,786,790,27955,27956
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Natural+History+of+%CE%B2-Cell+Autoimmunity+in+Young+Children+with+Increased+Genetic+Susceptibility+to+Type+1+Diabetes+Recruited+from+the+General+Population&rft.jtitle=The+journal+of+clinical+endocrinology+and+metabolism&rft.au=Kimpim%C3%A4ki%2C+T.&rft.au=Kulmala%2C+P.&rft.au=Savola%2C+K.&rft.au=Kupila%2C+A.&rft.date=2002-10-01&rft.issn=0021-972X&rft.eissn=1945-7197&rft.volume=87&rft.issue=10&rft.spage=4572&rft.epage=4579&rft_id=info:doi/10.1210%2Fjc.2002-020018&rft.externalDBID=n%2Fa&rft.externalDocID=10_1210_jc_2002_020018
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-972X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-972X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-972X&client=summon